CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues	$ 587,671	$ 556,237	$ 1,750,272	$ 1,665,594
Cost of service, inclusive of depreciation	337,563	311,628	986,033	924,093
General and administrative expenses:
Salaries and benefits	134,833	129,083	392,102	380,926
Non-cash compensation	6,726	6,612	21,987	18,968
Merger-related expenses	16,669	4,980	49,237	25,151
Depreciation and amortization	4,774	4,436	13,431	13,604
Other	56,777	57,287	173,320	180,467
Total operating expenses	557,342	514,026	1,636,110	1,543,209
Operating income	30,329	42,211	114,162	122,385
Other income (expense):
Interest income	2,017	1,304	5,361	2,452
Interest expense	7,772	8,021	23,786	23,040
Equity in earnings from equity method investments	1,891	1,252	4,316	9,366
Merger termination fee	0	0	0	(106,000)
Miscellaneous, net	2,522	1,201	5,391	5,262
Total other expense, net	(1,342)	(4,264)	(8,718)	(111,960)
Income before income taxes	28,987	37,947	105,444	10,425
Income tax expense	(12,473)	(12,331)	(41,763)	(40,381)
Net income (loss)	16,514	25,616	63,681	(29,956)
Net (income) loss attributable to noncontrolling interests	397	344	(69)	887
Net income (loss) attributable to Amedisys, Inc.	$ 16,911	$ 25,960	$ 63,612	$ (29,069)
Basic earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.52	$ 0.80	$ 1.94	$ (0.89)
Weighted average shares outstanding, basic (shares)	32,745	32,624	32,707	32,587
Diluted earnings per common share:
Net income (loss) attributable to Amedisys, Inc. common stockholders	$ 0.51	$ 0.79	$ 1.93	$ (0.89)
Weighted average shares outstanding, diluted (shares)	33,135	32,831	33,020	32,587